Literature DB >> 22280512

Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.

M Konsta, E Rallis, A Karameris, A Stratigos, P P Sfikakis, A Iliopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22280512     DOI： 10.1111/j.1468-3083.2011.04042.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  3 in total

Review 1.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

2.  Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling.

Authors:  Kayo Tanita; Taku Fujimura; Aya Kakizaki; Sadanori Furudate; Yoshiyuki Kusakari; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2015-07-24

3.  Abatacept in psoriatic arthritis: Case report and short review.

Authors:  Francesco Ursini; Saverio Naty; Emilio Russo; Rosa Daniela Grembiale
Journal:  J Pharmacol Pharmacother       Date:  2013-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.